ALPS ETF Trust's ALPS Medical Breakthroughs ETF (SBIO) has disclosed 101 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2023-11-30. The current portfolio value is calculated to be $84.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 2%.
ALPS Medical Breakthroughs ETF (SBIO)'s
Total Assets is $83.72 Mil , Total Liabilities is $33,050.00 , Net Assets is $83.69 Mil.
In ALPS Medical Breakthroughs ETF (SBIO)'s current portfolio as of 2023-11-30, the top 5 holdings are
Immunovant Inc (IMVT), Vaxcyte Inc (PCVX), Cerevel Therapeutics Holdings Inc (CERE), Alkermes PLC (ALKS) and ACADIA Pharmaceuticals Inc (ACAD),
not including call and put options.
ALPS Medical Breakthroughs ETF (SBIO) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for ALPS Medical Breakthroughs ETF (SBIO), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for ALPS Medical Breakthroughs ETF (SBIO), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for ALPS Medical Breakthroughs ETF.